Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity. It also provides Dupixent injection to treat atopic dermatitis and asthma in adults and pediatrics; Libtayo injection to treat metastatic or locally advanced cutaneous squamous cell carcinoma; Praluent injection for heterozygous familial hypercholesterolemia (HoFH) or clinical atherosclerotic cardiovascular disease in adults; REGEN-COV for covid-19; and Kevzara solution for treating rheumatoid arthritis in adults. In addition, the company offers Inmazeb injection for infection caused by Zaire ebolavirus; ARCALYST injection for cryopyrin-associated periodic syndromes, including familial cold auto-inflammatory syndrome and muckle-wells syndrome; and ZALTRAP injection for intravenous infusion to treat metastatic colorectal cancer; Evkeeza for treatment of HoFH; Ordspono for Follicular lymphoma and Diffuse large B-cell lymphoma; and Veopoz for CD55-deficient protein-losing enteropathy. Further, it develops product candidates for treating patients with eye, allergic and inflammatory, cardiovascular and metabolic, infectious, and rare diseases; and cancer, pain, and hematologic conditions. It has collaboration with Mammoth Biosciences, Inc. to research, develop and commercialize in vivo CRISPR-based gene editing therapies for multiple tissues and cell types; and with Sonoma Biotherapeutics, Inc. to discover, develop, and commercialize engineered regulatory T cell therapies. The company was incorporated in 1988 and is headquartered in Tarrytown, New York. Show more

Location: 777 Old Saw Mill River Road, Tarrytown, NY, 10591-6707, United States | Website: https://www.regeneron.com | Industry: Biotechnology | Sector: Healthcare


Market Cap

57.75B

52 Wk Range

$N/A - $N/A

Previous Close

$534.91

Open

$533.66

Volume

818,173

Day Range

$529.69 - $551.50

Enterprise Value

49.54B

Cash

8.349B

Avg Qtr Burn

N/A

Insider Ownership

1.90%

Institutional Own.

92.11%

Qtr Updated

03/31/25


Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & IndicationStage & EventCatalyst Date

Phase 4

Update

Evkeeza (evinacumab) Details
Homozygous familial hypercholesterolemia

Approved

Update

EYLEA HD (aflibercept) Details
Wet age-related macular degeneration , Diabetic macular edema

Approved

Quarterly sales

Kevzara (sarilumab) Details
Polymyalgia rheumatica

Approved

Quarterly sales

Dupixent® (dupilumab) (IL-4 IL-13) Details
Chronic rhinosinusitis with nasal polyps

Approved

Quarterly sales

Dupixent Details
Chronic obstructive pulmonary disease

Approved

Quarterly sales

EYLEA (aflibercept) Details
Diabetic retinopathy

Approved

Quarterly sales

Veopoz™ (pozelimab-bbfg) Details
Rare diseases, CD55-deficient protein-losing enteropathy , CHAPLE disease

Approved

Quarterly sales

Kevzara (sarilumab) Details
Polyarticular juvenile idiopathic arthritis

Approved

Quarterly sales

EYLEA (aflibercept) Details
Retinopathy of prematurity

Approved

Quarterly sales

Praluent® (alirocumab) Details
Heterozygous familial hypercholesterolemia

Approved

Quarterly sales

Libtayo® (cemiplimab) Details
Non-small cell lung carcinoma, Cutaneous squamous cell carcinoma

Approved

Quarterly sales

Approved

Quarterly sales

Approved

Quarterly sales

Approved

Quarterly sales

EYLEA HD® (aflibercept) Injection Details
Macular edema following retinal vein occlusion

PDUFA

Approval decision

Odronextamab Details
Follicular lymphoma, Diffuse large B cell lymphoma

PDUFA

Approval decision

Linvoseltamab (BCMAXCD3) Details
Blood cancer, Cancer, Multiple myeloma

PDUFA

Approval decision

Libtayo® (cemiplimab) Details
High-risk cutaneous squamous cell carcinoma (CSCC) after surgery

BLA

Acceptance for review

Itepekimab Details
Chronic obstructive pulmonary disease

Phase 3

Update

Phase 3

Initiation

Fianlimab + Libtayo® (cemiplimab) Details
Advanced malignancies, Melanoma

Phase 2/3

Data readout

Fianlimab + Libtayo® (cemiplimab) Details
Non-small cell lung carcinoma

Phase 2/3

Data readout

Phase 2

Data readout

Phase 1/2

Data readout

Linvoseltamab + Carfilzomib or Bortezomib Details
Relapsed/Refractory Multiple Myeloma

Phase 1b

Data readout

Phase 1

Data readout

Dupixent Details
Chronic inducible urticaria

Failed

Discontinued